Designing Survival: The Next Oncology Revolution

Jan de Vries · 2026-02-20

It's no secret that technology, especially AI, is reshaping healthcare from the ground up. Everything's moving faster, getting more precise, and honestly, it's about time. In cancer care, these changes aren't just noticeable—they're life-changing. We're catching diseases earlier, personalizing treatments like never before, and yes, helping more people survive. That whole shift? We call it precision medicine, and it's been a game-changer. But here's the thing. If precision medicine was the first big wave, the next one isn't just about better drugs. It's about rethinking survival itself. What if we stopped treating survival as just the finish line? What if we started designing for it from day one, making it the central goal of every therapy? That's where we're headed. ### The Outliers Who Show Us What's Possible In every type of cancer, there's a fascinating group of patients. They're the outliers. They don't just survive; they thrive in ways that defy the statistics. They respond to treatment remarkably well, bounce back quicker, and stay in remission longer. Our current tests can't always explain why. These exceptional survivors are like hidden treasure maps, showing us pathways to resilience we haven't fully charted yet. For years, research was laser-focused on the tumor—its genetics, how drugs fight it. But these outliers tell a bigger story. Their success isn't just about cancer biology. It's woven into their entire being: unique immune responses, specific metabolic patterns, even daily habits like sleep, diet, and how they manage stress. Their community ties and personal mindset matter too. This isn't just feel-good stuff; it's measurable, biological data. It makes you wonder, doesn't it? What if a patient's inherent resilience is just as critical as the treatment plan we give them? The future of beating cancer might depend less on fixing what's broken and more on understanding what's working spectacularly well for these remarkable people.  ### Building the Toolkit for Designed Survival So how do we turn this insight into action? Health innovators are starting to build the tools, and three approaches are leading the charge. First, we need better data. We're talking about large-scale resilience datasets. By tracking exceptional survivors over years—collecting genomic, immune, and metabolic info—we can spot the common threads. These aren't just biomarkers; they're the actual blueprints for long-term survival. Second, the rise of patient digital twins is a total game-changer. Five years ago, this was sci-fi. Now, AI can create a virtual model of a patient. We can simulate how their disease might progress, test different treatments, and identify their personal resilience indicators. It moves us from one-size-fits-all care to truly individualized strategy. Finally, we have closed-loop feedback systems. Think wearables and smart apps that track symptoms in real time. When a patient reports their energy levels, mood, or pain, that data isn't an afterthought—it's a vital medical signal. This continuous loop connects the biology of survival with the actual experience of living. Together, these tools are shifting oncology from a reactive field to a proactive design discipline.  ### What Comes Next: The Innovation Opportunity For entrepreneurs and investors, this opens up a whole new category. Resilience—or survival design—isn't just another niche. It expands the playing field beyond diagnostics and drugs into the entire ecosystem of living well with and beyond cancer. Key areas ripe for innovation include: - Platforms that create a resilience score, blending biological markers with lifestyle and behavioral data. - Real-time monitoring systems that give patients and doctors a continuous picture of health, not just snapshots from clinic visits. - Integrated support tools that help people manage the daily factors—nutrition, stress, connection—that science shows contribute to exceptional outcomes. As one researcher put it recently, "We're learning that survival isn't a passive outcome to be measured, but a capacity to be actively strengthened." The goal is no longer just to treat cancer. It's to design a path where every patient has the best possible chance to become one of those inspiring outliers. That's the next frontier, and it's being built right now.